133 related articles for article (PubMed ID: 24158080)
21. Clinical efficacy of primary combined androgen blockade for Japanese men with clinically localized prostate cancer unsuitable for local definitive treatment: a single institution experience.
Kobayashi M; Nukui A; Suzuki K; Kurokawa S; Morita T
Int J Clin Oncol; 2011 Dec; 16(6):630-6. PubMed ID: 21512893
[TBL] [Abstract][Full Text] [Related]
22. Ferumoxtran-10 MR lymphography for target definition and follow-up in a patient undergoing image-guided, dose-escalated radiotherapy of lymph nodes upon PSA relapse.
Weidner AM; van Lin EN; Dinter DJ; Rozema T; Schoenberg SO; Wenz F; Barentsz JO; Lohr F
Strahlenther Onkol; 2011 Mar; 187(3):206-12. PubMed ID: 21347637
[TBL] [Abstract][Full Text] [Related]
23. Incidental finding of non-Hodgkin's lymphoma in a patient affected by castration-sensitive prostate cancer: A case report.
Pirozzi A; Cartenì G; Scagliarini S; Fusco M; Riccardi F
Medicine (Baltimore); 2019 Mar; 98(11):e14805. PubMed ID: 30882658
[TBL] [Abstract][Full Text] [Related]
24. Targeted androgen pathway suppression in localized prostate cancer: a pilot study.
Mostaghel EA; Nelson PS; Lange P; Lin DW; Taplin ME; Balk S; Ellis W; Kantoff P; Marck B; Tamae D; Matsumoto AM; True LD; Vessella R; Penning T; Hunter Merrill R; Gulati R; Montgomery B
J Clin Oncol; 2014 Jan; 32(3):229-37. PubMed ID: 24323034
[TBL] [Abstract][Full Text] [Related]
25. Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910.
Pisansky TM; Hunt D; Gomella LG; Amin MB; Balogh AG; Chinn DM; Seider MJ; Duclos M; Rosenthal SA; Bauman GS; Gore EM; Rotman MZ; Lukka HR; Shipley WU; Dignam JJ; Sandler HM
J Clin Oncol; 2015 Feb; 33(4):332-9. PubMed ID: 25534388
[TBL] [Abstract][Full Text] [Related]
26. Predicting biochemical recurrence-free survival for patients with positive pelvic lymph nodes at radical prostatectomy.
von Bodman C; Godoy G; Chade DC; Cronin A; Tafe LJ; Fine SW; Laudone V; Scardino PT; Eastham JA
J Urol; 2010 Jul; 184(1):143-8. PubMed ID: 20478587
[TBL] [Abstract][Full Text] [Related]
27. Extended lymphadenectomy for high-risk prostate cancer in patients with chronic lymphocytic leukemia may not be necessary: a report of two cases.
Zhu Y; Wang Y; Qian Z; Pan J; Liu Q; Dong B; Xue W
BMC Cancer; 2019 Jul; 19(1):676. PubMed ID: 31288785
[TBL] [Abstract][Full Text] [Related]
28. [Multimodal therapy of prostate cancer - 2 case reports].
Lamche M; Bauer WA; Schramek P
Wien Med Wochenschr; 2008; 158(11-12):303-6. PubMed ID: 18641930
[TBL] [Abstract][Full Text] [Related]
29. Nodal Clearance Rate and Long-Term Efficacy of Individualized Sentinel Node-Based Pelvic Intensity Modulated Radiation Therapy for High-Risk Prostate Cancer.
Müller AC; Eckert F; Paulsen F; Zips D; Stenzl A; Schilling D; Alber M; Bares R; Martus P; Weckermann D; Belka C; Ganswindt U
Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):263-71. PubMed ID: 26853335
[TBL] [Abstract][Full Text] [Related]
30. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography.
Rigatti P; Suardi N; Briganti A; Da Pozzo LF; Tutolo M; Villa L; Gallina A; Capitanio U; Abdollah F; Scattoni V; Colombo R; Freschi M; Picchio M; Messa C; Guazzoni G; Montorsi F
Eur Urol; 2011 Nov; 60(5):935-43. PubMed ID: 21840116
[TBL] [Abstract][Full Text] [Related]
31. Cancer volume of lymph node metastasis predicts progression in prostate cancer.
Cheng L; Bergstralh EJ; Cheville JC; Slezak J; Corica FA; Zincke H; Blute ML; Bostwick DG
Am J Surg Pathol; 1998 Dec; 22(12):1491-500. PubMed ID: 9850175
[TBL] [Abstract][Full Text] [Related]
32. Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study.
Montironi R; Diamanti L; Santinelli A; Galetti-Prayer T; Zattoni F; Selvaggi FP; Pagano F; Bono AV
Pathol Res Pract; 1999; 195(4):201-8. PubMed ID: 10337657
[TBL] [Abstract][Full Text] [Related]
33. Prostatic adenocarcinoma presenting as isolated inguinal lymphadenopathy.
Doreswamy K; Karthikeyan VS; Nagabhushana M; Shankaranand B
BMJ Case Rep; 2015 Jul; 2015():. PubMed ID: 26153290
[TBL] [Abstract][Full Text] [Related]
34. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
Soga N; Arima K; Sugimura Y
Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
[TBL] [Abstract][Full Text] [Related]
35. A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.
Amato R; Stepankiw M; Gonzales P
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1629-34. PubMed ID: 23604530
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study.
Dorff TB; Flaig TW; Tangen CM; Hussain MH; Swanson GP; Wood DP; Sakr WA; Dawson NA; Haas NB; Crawford ED; Vogelzang NJ; Thompson IM; Glode LM
J Clin Oncol; 2011 May; 29(15):2040-5. PubMed ID: 21502546
[TBL] [Abstract][Full Text] [Related]
37. Regional Lymph Node Metastasis on Prostate Specific Membrane Antigen Positron Emission Tomography Correlates with Decreased Biochemical Recurrence-Free and Therapy-Free Survival after Radical Prostatectomy: A Retrospective Single-Center Single-Arm Observational Study.
Amiel T; Würnschimmel C; Heck M; Horn T; Nguyen N; Budäus L; Knipper S; Wenzel M; Rauscher I; Eiber M; Wang H; Maurer T
J Urol; 2021 Jun; 205(6):1663-1670. PubMed ID: 33535796
[TBL] [Abstract][Full Text] [Related]
38. Elective pelvic versus prostate bed-only salvage radiotherapy following radical prostatectomy: A propensity score-matched analysis.
Song C; Kang HC; Kim JS; Eom KY; Kim IA; Chung JB; Hong SK; Byun SS; Lee SE
Strahlenther Onkol; 2015 Oct; 191(10):801-9. PubMed ID: 26159555
[TBL] [Abstract][Full Text] [Related]
39. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
[TBL] [Abstract][Full Text] [Related]
40. Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.
Zilli T; Jorcano S; Escudé L; Linero D; Rouzaud M; Dubouloz A; Miralbell R
Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):316-22. PubMed ID: 24667210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
